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Abstract
Background:  Intravesical BCG immunotherapy is effective for preventing recurrence and
progression in none muscle-invasive bladder cancer but the dosing schedule and duration of
treatment remain empirical. The mechanisms by which intravesical BCG treatment mediates
antitumor activity are currently poorly understood.
Results: HeLa cell infected with Mycobacterium bovis Bacillus Calmette-Guérin(BCG) Tokyo which
were different multiplicity of infection(MOI). Proliferation of HeLa cell reduced in a dose-
dependent manner by live BCG. The cytoplasm of the HeLa cell showed variety lysosomal stages
by internalized and interacted BCG.
Conclusion: Proliferated Live BCG secreted the protein and depressed the growth of tumor. The
possibility for clinical introduction of BCG therapy for carcinoma reported with review of
literature.
Background
Intravesical BCG treatment has been demonstrated to be
an effective therapy for superficial transitional cell carci-
noma of the bladder though the mechanism of antitumor
effect still remained unclear. We studied to whether the
BCG depressed the growth of malignant tumor cell or not.
The proliferation of HeLa cells were inhibited by dose
dependent manner infected by live BCG. HeLa cell
infected by live and dead Mycobacterium bovis Bacillus Cal-
mette-Guérin(BCG) Tokyo revealed variety stage of lyso-
some and BCG in the cytoplasm of HeLa cell. The
internalization of live BCG into the HeLa cells did not
blocked by heparin and cytochalasin B. The internalized
live BCG secreted the secreted-protein and depressed the
growth of tumor cell. Live BCG inhibited the growth of
tumor cell by internalized and then the secreted protein in
cytoplasm of HeLa cells suggested the possibility of new
cancer therapy made of BCG combined with the drug
delivery system(DDS).
Results
The growth of HeLa cell was inhibited by dose dependent
manner cultured by live Mycobacterium bovis Bacillus Cal-
mette-Guérin(BCG) Tokyo (Figure 1). The proliferation of
HeLa cell was not inhibited when the MOI was 1. Live
BCG indicated more depressed the growth of HeLa cell
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than the each membrane(0.04 μg/ml, dry weight) or cyto-
plasm(0.02 μg/ml, dry weight) fraction of the BCG [1]
whose dosage were equivalent of MOI 100 (Figure 2).
Two days after cultured with live BCG (MOI 100), HeLa
cell showed vacuole and BCG in the cytoplasm (Figure
3A). Even one hour after cultured with live BCG, the cyto-
plasm of HeLa cell also revealed lysosome, residual body
and BCG (Figure 4A). There were several kinds of lyso-
some which indicated phagocytosis caused from internal-
ized BCG (Figure 4A, C). The myelin-like multilamellar
structure was also recognized in the cytoplasm of HeLa
cell by dead BCG one day after incubated [2] (Figure 4C).
Internalized live or dead (Figure 4A, C) BCG induced the
lysosomal activity of the HeLa cell. Four days after the
infected HeLa cell by live BCG showed the necrosis in
which the BCG kept its shape (Figure 4E). The internaliza-
tion of live BCG into the HeLa cells was found in their
cytoplasm with cytochalasin B [3] (100 μg/ml, Figure 3E)
or heparin [4] (0.001 U/ml.Figure 3F) was added into
each well before co-culture with HeLa cell respectively.
Immunoelectron microscope checked using polyclonal
antibodies of the MPB70 (secreted protein, α-antigen) [5-
7] and revealed the protein A gold reacted around the cell
wall of live BCG. (Figure 3B, D)
Discussion
Intravesical Bacillus Calmette-Guérin(BCG) therapy has
been effective in delaying or preventing recurrence and
progression for transitional cell carcinoma of bladder
although its outcome is still unpredictable [8]. The report
suggested that BCG interacted with tumor cells or inter-
nalized into them, and yet the role of cellular attachment
has been un-established. Therefore we initiate studied
Growth of HeLa cells were depressed by live and dead Mycobacterium bovis Bacillus Calmette-Guérin(BCG) Tokyo in each mul- tiplicity of infection(MOI) Figure 1
Growth of HeLa cells were depressed by live and dead Mycobacterium bovis Bacillus Calmette-Guérin(BCG) 
Tokyo in each multiplicity of infection(MOI). The growth of HeLa cells were inhibited in dose dependent manner cul-
tured by live BCG. The proliferation of HeLa cell was not inhibited when the MOI was 1.Cancer Cell International 2009, 9:30 http://www.cancerci.com/content/9/1/30
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using the TEM to better define for the interaction of HeLa
cells with BCG and leading to the hypothesis that live
BCG induced anti-tumor activity in the tumor cells. The
growth inhibition of the HeLa cell was more distinct by
live BCG to compare dead BCG, the cytoplasm or mem-
brane fraction of BCG [1]. Those indicated live BCG
invaded and proliferated in the tumor cells. Since BCG
infection inhibits the proliferation and differentiation of
HeLa cells, question arises as to the mechanism whether
inducing the bacteriological function from inside or out-
side. Several bacterial components have already been
reported the affected proliferation by infection [9]. The
possibility remains that poor nutrition of the cells caused
by intracellular proliferation of BCG as well as the BCG
stimulus on the cell surface receptor may also be involved
in the suppression of cellular proliferation and differenti-
ation [2].
Infection and growth of live BCG in the host cell and
released BCG-related cytokine were estimated as the rea-
sons for the depression of the tumor cells. MPB70 [7] (α
antigen) known to be an immunogenic mycobacterial
protein secreted in large amounts from culture filtrated of
Mycobacterium bovis Bacillus Calmette-Guérin(BCG)
Tokyo. This protein is thought to be crucial for binding
phagocytic cell having fibronectin receptors and this func-
tion might be a direct effect of BCG immuno-
therapy[10,11]. BCG is thought to bind to the bladder
wall via interaction between the bacterial antigen complex
and fibronectin [12]. Similar observations with fibronec-
tin attachment protein(FAP) demonstrated a Type I
response inducing IL12 and IFNγ production in normal
human peripheral blood lymphocytes. These data suggest
that a Type I response is required for antitumor activity by
BCG [13].
Growth depression of HeLa cell by different BCG component(MOI 100) Figure 2
Growth depression of HeLa cell by different BCG component(MOI 100). Live BCG depressed the tumor growth 
than that of the membrane(0.04 μg/ml, DW) and cytoplasm(0.02 μg/ml, DW) fraction each dosage were equivalent of MOI 
100.Cancer Cell International 2009, 9:30 http://www.cancerci.com/content/9/1/30
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Antitumor effects of BCG against superficial urinary blad-
der cancer were known to be strong when BCG is directly
infused into the bladder, but its immunological mecha-
nisms are poorly understood [14]. The internalization was
inhibited by cytochalasin B(200 μg/ml)[3]; conditions
known to inhibit phagocytosis [15]. Heparin (1.25 U/Kg)
also induced the aggregation of the local expression of
fibronectin and sequentially lessen FN-mediated BCG
attachment to bladder wall [4]. But cell membrane-
expressed fibronectin did not seem to be crucially
involved in the internalization of BCG by transitional
bladder cancer. A correlation between cellular fibronectin
expression and the ability of transitional cell carcinoma to
internalize BCG may be considered as a fortuitous coinci-
dence [16]. Our data showed the internalization of live
BCG into the HeLa cells were not blocked by heparin or
cytochalasin B. These phenomena suggested another pos-
sible reaction between the membrane of the HeLa cell and
BCG. Further experiments will be necessary to clarify the
biological relevant related between the internalization
and phagocytosis or autophagy which is associated with
the role of mycobacterial infection and intracellular kill-
ing of the cell [17]. Autophagy, the process in which cellu-
lar organelles are targeted for degradation in lysosome,
represents another potential tumor resistance mechanism
and further adding to the complexity of cell death path-
ways when tumor cells are exposed to various agents
[18,19]. IFN-γ induction of autophagy has not been previ-
ously reported in immune or phagocyte cells but has been
observed in HeLa cells [2,20]. We reported that mycobac-
terial infection induces the Th1-type immune response
lead on the immunological environment rich in IFN-α,
which is a suppressive mediator of the Th2-type immune
reaction [21]. Th1-stimulating cytokines played an impor-
tant role in BCG-induced macrophage cytotoxicity and
that combination of BCG with selected Th1-stimulating
cytokines, either supplemented or expressed by BCG, may
enhance the effect of BCG in the treatment of bladder can-
cer patients [22]. Early stages of BCG infection into oste-
oblastic-like cell (MC3T3-E1) secreted IL-6 and then
A; HeLa cell and live BCG were co-cultured after 2 days Figure 3
A; HeLa cell and live BCG were co-cultured after 2 days. There were vacuole(V) and BCG(↑) in the cytoplasm of HeLa 
cell. B, D; Protein A gold(↑) attached on the cell wall of BCG in the HeLa cell co-cultured with live BCG after two days by 
immunoelectron microscope (anti MPB70 polyclonal antibody). C; Dead BCG did not reacted at the cell wall. Cytochalasin B 
(E, 100 μg/ml) or Heparin (F, 0.001 U/ml) was added in each culture well of HeLa cell before infection by live BCG also showed 
the internalized BCG(↑) after 24 hours. N; NucleusCancer Cell International 2009, 9:30 http://www.cancerci.com/content/9/1/30
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depressed the proliferation of host [23]. The findings that
live BCG infected and internalized in the HeLa cells as
shown here, lysosomal activity is an important connec-
tion between immune mediator and associated intracellu-
lar depression of the host cells. These data suggested that
live BCG invaded and proliferated in the cell then released
the BCG-related protein have direct effect to inhibit the
growth of the host.
The novel method such as using target would allow fur-
ther improve the bacteria to satisfy a variety of require-
ments for clinical use. These therapies elicit active
immune response against the tumor so that they kill off
primary as well as metastases [24]. Successful cancer ther-
apy required close contact between BCG and tumor cells,
a host capable of developing and expressing delayed
hypersensitivity type reactions to mycobacterial antigens,
limited tumor size and an adequate number of viable
BCG [25]. It is also necessary to establish the effective drug
delivery system(DDS) to be internalized into malignant
cell in vivo treatment [26]. The difference between the live
and dead BCG which internalized in the cytoplasm of
HeLa cell is the existence of secreted protein or not. BCG
interacted with tumor cells and were internalized into
them suggested future development of anti-tumor agents
made from bacterial cell wall [27]or secreted protein [28].
Conclusion
Live BCG depressed the growth of the HeLa cell by dose
dependent manner.
Live BCG internalized and secreted protein in the host cell
suggested the depression of tumor cell.
Methods
HeLa cell
HeLa cell (1 × 105 cells/ml) were maintained in minimal
essential medium (MEM, Gibco BRL, Tokyo Japan) sup-
plemented with 10% fetal bovine serum and 100,000 U/
1 penicillin at 37°C in humidified atmosphere with 5%
CO2. The cultured medium was replaced every 3 days.
Cells were rinsed 2 times with phosphates-buffered saline
(PBS; 137 mM NaCl, 2.7 mM KCl, 8.1 mM NaH2PO4)
before addition of fresh medium.
Bacillus Calmette-Guérin(BCG) [7,1,29]
Mycobacterium bovis Bacillus Calmette-Guérin(BCG)
Tokyo was cultured in Middle brock 7H9 broth (Difco
Laboratories, Detroit, MI, USA) supplemented with 10%
Albumin-dextrose-catalase(ADC; Difco laboratories)
enrichment and 0.1% Tween 80. The cells(approximate 8
× 1010 cells/ml) were harvested with shaking at 37°C until
0.8 of an optical density(OD) at 590 nm. It was centri-
A, B; HeLa cells were infected with live BCG after 1 hour and showed BCG(↑), residual body(RB) and lysosome(L) in the cyto- plasm Figure 4
A, B; HeLa cells were infected with live BCG after 1 hour and showed BCG(↑), residual body(RB) and lyso-
some(L) in the cytoplasm. Different stages of the lysosomal activity were induced by internalized BCG. C, D; HeLa cells 
were co-cultured with dead BCG(↑) which were also internalized after 1 hour and showed the lysosome and vacuole. E, F; 
HeLa cells co-cultured with live BCG after four days. HeLa cell showed lack of cell membrane(↑CM), lost of cytoplasm(↑CP), 
nuclear degeneration(N) and BCG(↑). The shape of BCG was keeping in the HeLa cell.Cancer Cell International 2009, 9:30 http://www.cancerci.com/content/9/1/30
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fuged and the pelletized cells re-suspended with MEM
were divided and used for experiments. Dead BCG dosage
(1 × 107 cells/ml) as MOI 100 was prepared and treated by
an autoclave (121°C, 10 min).
Fraction of BCG membrane and cytoplasm [1]
BCG(Tokyo) was sedimented (3,000 × g, 10 min, 4°C),
suspended in TMNSH buffer, and lysed by sonication in a
Bioruptor UCD-200T sonicator (Toso, Tokyo, Japan). The
cell lysate was centrifuged at 10,000 × g for 10 min at 4°C
twice. The supernatant was then centrifuged at 30,000 × g
for 30 min at 4°C. The pellet was used as the membrane
fraction.
The supernatant solution was centrifuged under the same
conditions, and the supernatant thus obtained was then
centrifuged at 105,000 × g for two hours at 4°C. The pellet
was used as the cytoplasm fraction.
The pellets obtained in each step were suspended in
TMNSH buffer. Freeze drying membrane and cytoplasm
fraction were prepared 0.04 μg/ml and 0.02 μg/ml respec-
tively for the experiment as MOI 100 and keeping at the
department of oral bacteriology Nagasaki University. BCG
also had been cultured in the same department.
Polyclonal antibody [7]of MPB70 (secreted protein,   
antigen) [5,6,10]
Purified MPB70 was provided by Dr. Nagai. BALB/c mice
at 7-10 weeks of age were immunized intravenously with
MPB 70 (10 μg diluted 200 ul of PBS) which was served as
the most abundant protein in the culture filtrate from
BCG(Tokyo). After 30 days, same amount of MPB 70 was
injected intraperitoneally to boost the immune response.
After 1 week later, sera were collected from the eye vein of
immunized mice and pooled at -80°C until use. Animal
had been keeping at animal center of Nagasaki Univ.
HeLa and BCG cells co-culture
Two millimeter of HeLa cells (1 × 105/ml) were inocu-
lated in 24-well plates and cultured for 1 days. Then BCG
at various doses and type were added to the wells. After 72
hours fresh MEM exchanged one ml.
Different BCG dosage even, ten and hundred times of
multiplicity of infection (MOI) BCG were prepared and
cultured with HeLa cell.
Growth inhibition of HeLa cell checked by its fraction of
membrane (0.04 μg/ml, Dry weight) and cytoplasm (0.02
μg/ml, Dry weight) were also prepared as equivalent dos-
age of MOI 100 and added in the medium of HeLa cells.
Internalization of the BCG checked using each cytochala-
sin B (100 μg/ml, Wako pure C.I. Japan) or heparin
sodium (0.001 U/ml, OSTUKA Pharm. Japan) was added
into the well before co-cultured with HeLa cell respec-
tively.
Cell count
Every other day during the incubation period with the
HeLa and BCG, MEM changed to the usual saline solution
and treated 2% tripsin treated for 5 minutes. HeLa cells
were mounted on the erythrocytometer after 0.3% trypan-
blue stain. The number of cells expressed as the mean for
three times.
Transmission electron microscope (TEM) [28]
The HeLa cell washed in the normal saline solution and
centrifuged. The cells were fixed in solution of 2% glutar-
aldehyde in 0.1 M phosphate buffer solution, pH 7.3 for
2 hours and 1% osmium tetraoxide for 2 hours. After two
times washed PBS and water the cells were dehydrated
with increasing concentrations of ethanol; and gradually
infiltrated with Epon 812. Before inspection by TEM the
trimmed bloc of epon was orientated and stained with
toluidine blue for light microscopy orientation. The
ultrathin section with silver to gold interference color
were picked up in a nickel grid and stained with uranyl
acetate and lead nitrate in the usual manner.
For Immuno-TEM HeLa cell fixed 1% paraformaldehyde
at 4°C for one hour. Then dehydrated in ethanol and
embedded by LR white(Okenshoji, Japan) for 2 days at -
20°C. The same interference color picked up on the collo-
dion coated mesh (Nissinn EM, Japan) specimens were
reacted with 2% hydrogen peroxide for 30 minutes twice
and blocked bovine serum for 30 minutes. They were
reacted with hundred times diluted anti-sera (polyclonal
Aanti-MPB70) for 12 hours at 8°C and protein A gold (15
nm, FUNAKOSI, Japan) for three hours at room tempera-
ture in moisture chamber and then double stained for 5
minutes each. The specimens were examined in a H800
electron microscope (Hitachi, Japan) operating at 75 kV.
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